- ICE3 trial will be finalized in Q1 2024
- IceCure's distributor in India, Novomed, exhibited ProSense® and
received a high level of interest from doctors, clinics, and
hospitals
- ProSense was used to perform India's first breast cryoablation procedure in
June 2023
CAESAREA, Israel, Oct. 30,
2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure" or the "Company"), developer of the ProSense®
System, a minimally-invasive cryoablation technology that destroys
tumors by freezing as an alternative to surgical tumor removal,
today announced its participation in the 10th Annual
Conference of the Breast Imaging Society of India (BISICON 2023) in conjunction with its
in-country distributor, Novomed, from October 27-29, 2023. ProSense® was featured at
Novomed's booth where doctors had the opportunity to get hands-on
experience with the cryoablation system.
ProSense® was installed and inaugurated at Kovai Medical Center
and Hospital in May 2023 and in
June 2023 the first breast cancer
cryoablation procedure in India
was successfully conducted.
Results from IceCure's ICE3 study of ProSense®, the largest U.S.
controlled multicenter clinical trial ever performed for liquid
nitrogen-based cryoablation of early-stage breast cancer, were
featured in a talk given by the study's Co-Primary Investigator,
Dr. Kenneth R. Tomkovich, during a
session titled "Pushing the boundaries—Minimally invasive cancer
therapies". Interim results, which were previously published,
show a 96.91% recurrence free rate, 100% safety, and 100% doctor
and patient satisfaction with cosmetic results. Recent
independently conducted studies in Europe have demonstrated similar results. The
ICE3 trial is expected to be finalized in the first quarter of
2024.
Dr. Tomkovich, Diagnostic and Interventional Radiologist
with Princeton Radiology, CentraState Medical Center and Penn
Princeton Medical Center, commented, "The ICE3 interim
results show that early-stage breast cancer patients are achieving
recurrence-free results that are comparable to surgical lumpectomy
which is the current gold standard. Given the additional benefits
of image guided cryoablation using ProSense®️ including the ability
to be performed in an outpatient setting requiring only local
anesthetic, minimal recovery time, and excellent cosmetic outcomes,
cryoablation is proving to be an excellent choice for the right
patients. I'm pleased to present these findings and share my
personal experience with ProSense®️ at medical conferences as
I believe the wider adoption of cryoablation for breast cancer will
improve outcomes and the quality of life for women around the
world."
"ProSense had a very positive reception, both at Novomed's booth
and at Dr. Tomkovich's presentation," stated IceCure's VP of
Business Development and Global Marketing, Tlalit Bussi Tel Tzure.
"In conjunction with Novomed, we are eager to have ProSense® rolled
out to more hospitals in India.
According to information published by Cytecare Cancer Hospitals, a
cancer hospital located in Bangalore,
India, one in 28 women in India is likely to develop breast cancer
during her lifetime, and ProSense® can provide these women and
their doctors the option of choosing a minimally invasive procedure
with very safe and effective results."
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses: the
expected conclusion of its ICE3 study in the first quarter of 2024
and that ProSense® can provide women that develop breast cancer and
their doctors the option of choosing a minimally invasive procedure
with very safe and effective results. Historic results of
scientific research and clinical and preclinical trials do not
guarantee that the conclusions of future research or trials will
suggest identical or even similar conclusions. Because such
statements deal with future events and are based on IceCure's
current expectations, they are subject to various risks and
uncertainties and actual results, performance, or achievements of
IceCure could differ materially from those described in or implied
by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject
to other risks and uncertainties, many of which are beyond the
control of the Company, including those set forth in the Risk
Factors section of the Company's Annual Report on Form 20-F for the
year ended December 31, 2022 filed
with the SEC on March 29, 2023, and
other documents filed with or furnished to the SEC which are
available on the SEC's website, www.sec.gov. The Company undertakes
no obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecures-ice3-trial-results-demonstrating-96-91-recurrence-free-rate-featured-in-a-presentation-at-bisicon-2023-in-india-301971209.html
SOURCE IceCure Medical